CME ACCREDITATION

Continuing Medical Education (CME) Information 

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Commercial Support^SM of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational program process—from development through implementation—to ensure independence of educational activities. IASLC policies are outlined below.

In compliance with ACCME Standards, each individual in a position to control the content of an educational activity must disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant” financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Individuals who refuse to disclose relevant financial relationships are not allowed to have control of, or responsibility for, the development, management, presentation or evaluation of CME activities. All disclosures are reviewed for potential conflicts, and appropriate steps for resolution are taken when needed.  Additionally, individuals must agree to comply with specific rules (attestations) to ensure content is balanced and evidence-based, does not promote the business interests of a commercial entity, and conforms to the generally accepted standard of experimental design, data collection and analysis. Presenters are also required to clearly identify any non-FDA approved uses of products. IASLC also monitors presentations for quality and compliance through direct observation (IASLC staff and CME committee members), and through member feedback on evaluation surveys.

For the IASLC 2019 North America Conference on Lung Cancer (NACLC 2019), disclosure information will be available for viewing on the conference website. Presenters are also required to include a disclosure slide listing all relevant financial relationships with commercial interests. CME related questions should be directed to IASLC at [email protected].

CREDIT STATEMENT

The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates this live activity for a maximum of 11 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

This conference is an educational and scientific event which will cover key aspects of the diagnosis and management of lung cancer and other thoracic malignancies. With a multi-disciplinary program including invited lectures, parallel oral abstracts sessions and poster presentations, participants will learn about prevention, screening and disparities in uptake of screening, surgical management, advanced radiation therapy techniques, novel therapeutics including targeted agents and immunotherapy, and the latest in diagnostics and pathology of lung cancer and other thoracic malignancies. Talks will cover multi-disciplinary implementation of the latest knowledge into daily practice.

TARGET AUDIENCE

The 2019 North America Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants, nurses and other research professionals.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Examine scientific advances in thoracic cancer including the pathogenesis, biology, and mechanisms of drug interactions that can be used to make evidence-based diagnosis and treatment decisions.
2. Synthesize cutting edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
3. Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.
4. Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.
5. Collaborate on multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.
6. Engage and empower patients to become active participants in their treatment.

OFFICIAL LANGUAGE

The official language of the IASLC 2019 North America Conference on Lung Cancer is English.

DISCLAIMER

The information presented at the IASLC 2019 North America Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.